Sara A. Scott
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sara A. Scott has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Craig C. Hofmeister
Department of Hematology/Medical Oncology, Emory University, Atlanta, GA
3 shared publications - Vikas A. Gupta
Department of Hematology/Medical Oncology
3 shared publications - Ajay K. Nooka
Winship Cancer Institute, Emory University, Atlanta, USA
2 shared publications - Jonathan L. Kaufman
Winship Cancer Institute, Emory University, Atlanta, GA
2 shared publications - Madhav V. Dhodapkar
Fred Hutchinson Cancer Center, Seattle, Washington, United States
2 shared publications - Sagar Lonial
Winship Cancer Institute, Emory University, Atlanta, GA
2 shared publications
Latest Publications
- Open Access
- 31 July 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (19)
Early CD4+ T cell proliferation and chronic T cell engagement impact myeloma outcomes following T cell engager therapy
- 31 July 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (19)
Open AccessEarly CD4+ T cell proliferation and chronic T cell engagement impact myeloma outcomes following T cell engager therapy
- Open Access
- 8 April 2025
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 25 (9) , 656-660
Feasibility and Safety of Outpatient Model for Administration of Bispecific Antibodies: Proceedings from an International Myeloma Society 21st Annual Meeting Oral Abstract
- 8 April 2025
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 25 (9) , 656-660
Open AccessFeasibility and Safety of Outpatient Model for Administration of Bispecific Antibodies: Proceedings from an International Myeloma Society 21st Annual Meeting Oral Abstract
- Top Cited PapersOpen Access
- 20 December 2023
- Published by Springer Nature in Blood Cancer Journal
- Vol. 13 (1) , 1-3
Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: A single-center experience
- 20 December 2023
- Published by Springer Nature in Blood Cancer Journal
- Vol. 13 (1) , 1-3
Top Cited PapersOpen AccessProphylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: A single-center experience
- 1 March 2023
- Published by Wiley in Transplant Infectious Disease
- Vol. 25 (2) , e14045
Incidence of breakthrough fungal infections on isavuconazole prophylaxis compared to posaconazole and voriconazole
Background: Invasive fungal infections (IFIs) are a common infectious complication during the treatment of acute myeloid leukemia (AML), high‐risk myelodysplastic syndrome (MDS) or post hematopoietic cell transplantation (HCT). For these patients, the National Comprehensive Cancer Network recommends posaconazole or voriconazole for IFI prophylaxis. In clinical practice, however, there has been increased use of isavuconazole due to favorable pharmacokinetic and pharmacodynamic parameters despite limited data for this indication. The comparative prophylactic efficacy of antifungals in this patient population has not been reported, and an analysis is warranted.Methods: This retrospective, matched cohort, single‐center study, included AML, MDS, or HCT patients who began treatment or underwent transplant between January 1, 2015 and July 31, 2021. Isavuconazole patients were matched 1:2 with patients receiving posaconazole or voriconazole prophylaxis.Results: A total of 126 patients were included, 42 received isavuconazole, 81 received posaconazole, and three received voriconazole. The majority of patients were male receiving secondary IFI prophylaxis while receiving steroids for treatment of GVHD. The incidence of possible, probable or proven IFI was 16.7% in the isavuconazole group compared to 10.7% in the posaconazole and voriconazole group (OR 1.28, 95% CI −0.9–1.4; p = .67). Hepatotoxicity occurred in 16 total patients, 14 receiving posaconazole and two receiving isavuconazole.Conclusion: Patients who received isavuconazole prophylaxis during AML induction therapy or post‐HCT experienced a similar incidence of breakthrough fungal infections compared to those who received posaconazole or voriconazole. These results suggest no difference in antifungal prophylactic efficacy; however larger prospective comparative studies are needed. image
- 1 March 2023
- Published by Wiley in Transplant Infectious Disease
- Vol. 25 (2) , e14045
Incidence of breakthrough fungal infections on isavuconazole prophylaxis compared to posaconazole and voriconazole
Background: Invasive fungal infections (IFIs) are a common infectious complication during the treatment of acute myeloid leukemia (AML), high‐risk myelodysplastic syndrome (MDS) or post hematopoietic cell transplantation (HCT). For these patients, the National Comprehensive Cancer Network recommends posaconazole or voriconazole for IFI prophylaxis. In clinical practice, however, there has been increased use of isavuconazole due to favorable pharmacokinetic and pharmacodynamic parameters despite limited data for this indication. The comparative prophylactic efficacy of antifungals in this patient population has not been reported, and an analysis is warranted.Methods: This retrospective, matched cohort, single‐center study, included AML, MDS, or HCT patients who began treatment or underwent transplant between January 1, 2015 and July 31, 2021. Isavuconazole patients were matched 1:2 with patients receiving posaconazole or voriconazole prophylaxis.Results: A total of 126 patients were included, 42 received isavuconazole, 81 received posaconazole, and three received voriconazole. The majority of patients were male receiving secondary IFI prophylaxis while receiving steroids for treatment of GVHD. The incidence of possible, probable or proven IFI was 16.7% in the isavuconazole group compared to 10.7% in the posaconazole and voriconazole group (OR 1.28, 95% CI −0.9–1.4; p = .67). Hepatotoxicity occurred in 16 total patients, 14 receiving posaconazole and two receiving isavuconazole.Conclusion: Patients who received isavuconazole prophylaxis during AML induction therapy or post‐HCT experienced a similar incidence of breakthrough fungal infections compared to those who received posaconazole or voriconazole. These results suggest no difference in antifungal prophylactic efficacy; however larger prospective comparative studies are needed. image
- 3 June 2022
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 30 (10) , 8501-8509
Inpatient primary prophylaxis of cancer-associated thromboembolism (CAT)
Purpose Cancer-associated thrombosis (CAT) increases morbidity and mortality in oncology patients. The risk of CAT is increased with hospitalization for acute medical illness. The goal of this review will be to examine the available evidence for (1) risk assessment and (2) primary thromboprophylaxis, (3) international published guideline recommendations, and (4) future directions to manage oncology patients admitted for an acute medical illness. Methods A review was performed for each subject to gather information on the available evidence and recommendations available for oncology patients hospitalized for an acute medical illness. Results Risk assessments for thrombosis are primarily developed and validated in the general population. There is not a risk assessment that has specifically been developed and validated in oncology patients hospitalized for an acute medical illness. Most evidence for thromboprophylaxis of oncology patients is from sub-group analysis of larger randomized-controlled trials in the general population. Evidence is conflicting and suggests an individualized approach evaluating the risk-benefit of thromboprophylaxis. The strength of recommendations of international guidelines is limited because of the available evidence. Guidelines usually recommend utilizing and/or offering thromboprophylaxis to oncology patients hospitalized for an acute medical illness barring contraindications. Future evidence needs to improve risk assessments and knowledge of the appropriate agent, dose, and duration of thromboprophylaxis if indicated. Conclusion Evidence for risk assessments and primary prophylaxis for oncology patients hospitalized for acute medical illness appears limited, with many research opportunities available to improve understanding on management of this patient population.
- 3 June 2022
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 30 (10) , 8501-8509
Inpatient primary prophylaxis of cancer-associated thromboembolism (CAT)
Purpose Cancer-associated thrombosis (CAT) increases morbidity and mortality in oncology patients. The risk of CAT is increased with hospitalization for acute medical illness. The goal of this review will be to examine the available evidence for (1) risk assessment and (2) primary thromboprophylaxis, (3) international published guideline recommendations, and (4) future directions to manage oncology patients admitted for an acute medical illness. Methods A review was performed for each subject to gather information on the available evidence and recommendations available for oncology patients hospitalized for an acute medical illness. Results Risk assessments for thrombosis are primarily developed and validated in the general population. There is not a risk assessment that has specifically been developed and validated in oncology patients hospitalized for an acute medical illness. Most evidence for thromboprophylaxis of oncology patients is from sub-group analysis of larger randomized-controlled trials in the general population. Evidence is conflicting and suggests an individualized approach evaluating the risk-benefit of thromboprophylaxis. The strength of recommendations of international guidelines is limited because of the available evidence. Guidelines usually recommend utilizing and/or offering thromboprophylaxis to oncology patients hospitalized for an acute medical illness barring contraindications. Future evidence needs to improve risk assessments and knowledge of the appropriate agent, dose, and duration of thromboprophylaxis if indicated. Conclusion Evidence for risk assessments and primary prophylaxis for oncology patients hospitalized for acute medical illness appears limited, with many research opportunities available to improve understanding on management of this patient population.